A phase 1/1b multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI3726 in patients with metastatic, castration-resistant prostate cancer who have received prior treatment with abiraterone or enzalutamide.
Fleming M, Cathomas R, Petrylak D, Wang J, Bander N, Zammarchi F, van Berkel P, Cho S, Elgeioushi N, Bothos J, Scheuber A, de Bono J. A phase 1/1b multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI3726 in patients with metastatic, castration-resistant prostate cancer who have received prior treatment with abiraterone or enzalutamide. Journal Of Clinical Oncology 2017, 35: tps5088-tps5088. DOI: 10.1200/jco.2017.35.15_suppl.tps5088.Peer-Reviewed Original ResearchProstate-specific membrane antigenCastration-resistant prostate cancerDose-expansion studyAbiraterone acetateProstate cancerDose escalationAntitumor activityPrior treatmentTaxane-based chemotherapyDose-limiting toxicityFurther treatment optionsAnti-PSMA antibodyVivo antitumor activityTarget enrollmentTreatment optionsTherapeutic advancesPreclinical modelsPatientsMembrane antigenSecondary objectiveCancerMCRPCMulticenterTolerabilityExpression levels